OBJECTIVE: To evaluate the effect of using the t:slim X2 insulin pump with Control-IQ technology (hereafter, Control-IQ ; Tandem Diabetes Care, Inc) on glycemic status in individuals with type 2 diabetes (T2D) who switched from multiple daily insulin injections.
STUDY DESIGN: This 12-month retrospective analysis utilized data from the Tandem t:connect web application and customer relationship management database, encompassing individuals covered by commercial insurers, Medicaid, and Medicare.
METHODS: We assessed changes in glucose management indicator (GMI) values from baseline hemoglobin A 1c (HbA 1c ) at 12 months relative to Healthcare Effectiveness Data and Information Set (HEDIS) quality measures (HbA 1c or GMI: < 8.0% [in control] and > 9.0% [poor control]). The primary outcome was the proportion of individuals who met the recommended HEDIS measure. Achievement of a GMIof less than 7.0% was included as a secondary outcome. Changes in glycemic outcomes and the proportion of individuals meeting the national threshold were analyzed.
RESULTS: The analysis included 1737 individuals with T2D who had baseline HbA 1c data. Following initiation of Control-IQ, the number of individuals who met the HEDIS (GMI < 8.0%) measure increased from 755 (43.5%) at baseline to 1545 (88.9%) at 12 months ( ∆  = 104.6%). The number of individuals who achieved a GMI of less than 7% increased from 282 (16.2%) to 678 (39.0%) ( ∆  = 140.4%). The number of individuals with HbA 1c greater than 9.0% at baseline decreased from 514 (29.6%) at baseline to 10 (0.6%) ( ∆  = -98.1%) at 12 months.
CONCLUSIONS: A greater proportion of individuals who transitioned to Control-IQ therapy achieved the HEDIS goal for in-control diabetes across all payer types, as measured by GMI.